Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 74

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 74
---
-18 NLS PHARMACEUTICS LTD.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

The following table summarizes unvested share option activity for the six-month period ended June 30, 2025:

|                              |     | Non-Vested 
    Options |     | Weighted   
 Average    
 Grant date 
 Fair Value |       |
|:-----------------------------|:----|-----------:|:----|:-----------|------:|
| Balance at December 31, 2024 |     |     15,301 |     | $          | 41.11 |
| Granted                      |     |          — |     |            |       |
| Vested                       |     |      5,048 |     |            |       |
| Forfeited                    |     |          — |     |            |       |
| Balance at June 30, 2025     |     |     10,253 |     | $          | 37.99 |

The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair value of the Company’s common shares for those share options that had exercise prices lower than the fair value of the Company’s common shares. The share price as of June 30, 2025, was $ and the aggregate intrinsic value for options outstanding and expected to vest each year was nil. The intrinsic value of exercisable options was nil as the exercise price was greater than the share price.

Share-based compensation expense for the six months ended June 30,2025 and 2024, was $ and $, respectively, and is included in general and administrative expenses. As of June 30, 2025, total unrecognized share-based compensation expense relating to unvested share options was $. This amount is expected to be recognized over a weighted-average period of years.

Note 7 Related party consulting agreements: The Company entered into consulting agreements with several of its senior management. In February 2021, the Company entered into a consulting agreement with Mr. Eric Konofal, the Company’s current Chief Scientific Officer, pursuant to which the Company agreed to pay Mr. Konofal a daily rate of CHF 2,000for his services. The consulting agreement may be terminated by either party upon 30 days’ written notice or immediately by the Company in the event of a material breach by Mr. Konofal that cannot be cured. The consulting agreement contains customary confidentiality provisions